Bristol Myers sees FY24 adjusted EPS $7.10-$7.40, consensus $7.00

Bristol Myers Squibb provides its 2024 non-GAAP EPS guidance range of $7.10 – $7.40. Total 2024 revenues are expected to increase by low single-digits; Excluding foreign exchange, total revenues are expected to increase by low single-digits. Non-GAAP Gross margin is expected to be approximately 74%. Non-GAAP Operating expenses are expected to increase by low single-digits. Other Income/(Expense) is expected to be approximately $250M. “The 2024 financial guidance excludes the impact of any potential future strategic acquisitions, including the announced planned acquisitions of RayzeBio and Karuna, divestitures, specified items, and the impact of future Acquired IPRD charges,” the company stated.